Concourse Financial Group Securities, Inc. Inventiva S.A. Transaction History

Concourse Financial Group Securities, Inc.

  • $0
  • Q2 2025
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
100.0%
Previous 100.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$2.94 - $3.89 $0 - $0
0 New
0 $0
Q1 2025

May 14, 2025
BUY
$2.11 - $3.26 $0 - $0
0 New
0 $0
Q4 2024

Feb 13, 2025
BUY
$1.65 - $2.77 $0 - $0
0 New
0 $0
Q3 2024

Oct 10, 2024
BUY
$1.79 - $2.97 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024
BUY
$2.62 - $3.89 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024
BUY
$3.27 - $4.7 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$3.64 - $4.55 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$3.41 - $4.44 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$3.41 - $4.44 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$2.42 - $4.88 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$3.47 - $6.53 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$3.66 - $7.05 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$3.69 - $6.05 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$5.61 - $12.15 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$10.51 - $13.66 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$12.75 - $15.65 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$10.73 - $14.85 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$13.0 - $15.67 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$12.55 - $19.0 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$11.35 - $14.5 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$9.87 - $13.42 $0 - $0
0 New
0 $0

Others Institutions Holding IVA

# of Institutions
12
Shares Held
4.95M
Call Options Held
0
Put Options Held
0
View Full List

About Inventiva S.A.

IVA Quotes by TradingView
  • Ticker IVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,134,200
  • Market Cap $180M
  • Description
  • Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...
More about IVA
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email